Skip to main content
. 2015 Jan 31;2015:638934. doi: 10.1155/2015/638934

Table 1.

The fifty citation classics in osteoporosis and related research.

Rank Paper Absolute number of citations Citation density Level of evidence
1 M. R. Urist, “Bone - formation by autoinduction,” Science, vol. 150, pp. 893–899, 1965. 3056 63,6 N/A

2 D. L. Lacey, E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y. X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W. J. Boyle, “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,” Cell, vol. 93, pp. 165–176, 1998. 2768 184,5 N/A

3 J. M. Wozney, V. Rosen, A. J. Celeste, and L. M. Mitsock, “Novel regulators of bone-formation - molecular clones and activities,” Science, vol. 242, pp. 528–1534, 1988. 2662 106,4 N/A

4 W. S. Simonet, D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Luthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw Gegg, T. M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, and W. J. Boyle, Cell, vol. 89, pp. 309–319, 1997. 2629 164,3 N/A

5 H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda, “Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 3597–3602, 1998. 2206 147 N/A

6 T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Sasaki, K. Deguchi, Y. Shimizu, R. T. Bronson, Y. H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, and T. Kishimoto, “Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to aturational arrest of osteoblasts,” Cell, vol. 89, pp. 755–764, 1998. 2132 133,2 N/A

7 S. R. Cumming, M. C. Nevitt, W. S. Browner, K. Stone, K. M. Fox, K. E. Ensrud, J. C. Cauley, D. Black, and T. M. Vogt, “Risk-factors for hip fracture in white women,” The New England Journal of Medicine, vol. 332, pp. 767–773, 1995. 2102 116,7 I

8 D. M. Black, S. R. Cumming, D.B. Karpf, J. A. Cauley, D. E. Thompson, M. C. Nevitt, D. C. Bauer, H. K. Genant, W. L. Haskell, R. Marcus, S. M. Ott, J. C. Torner, S. A. Quandt, T. F. Reiss, and K. E. Ensrud, “Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures,” Lancet, vol. 348, pp. 1535–1541, 1996. 2067 121,5 I

9 M. C. Chapuy, M. E. Arlot, F. Duboeuf, J. Brun, B. Crouzet, S. Arnaud, P. D. Delmas, and P. J. Meunier, “Vitamin-D(3) and calcium to prevent hip-fractures in elderly women,” The New England Journal of Medicine, vol. 23, pp. 1637–1642, 1992. 1771 84,3 I

10 Y. Y. Kong, H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C. R. Dunstan, D. L. Lacey, T. W. Mak, W. J. Boyle, and J. M. Penninger, “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,” Nature, vol. 397, pp. 315–323, 1999. 1741 124,3 N/A

11 B. Ettinger, D. M. Black, B. H. Mitlak, R. K. Knickerbocker, T. Nickelsen, H. K. Genant, C. Christiansen, P. D. Delmas, J. R. Zanchetta, J. Stakkestad, C. C. Gluer, K. Krueger, F. J. Cohen, S. Eckert, K. E. Ensrud, L. V. Avioli, P. Lips, and S. R. Cummings, “Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene,” The Journal of the American Medical Association, vol. 282, pp. 637–645, 1999. 1732 123,7 I

12 B. L. Riggs, and L. J. Melton, “Involutional Osteoporosis,” The New England Journal of Medicine, vol. 314, pp. 1676–1686, 1986. 1719 63,6 N/A

13 D. Marshall, O. Johnell, and H. Wedel, “Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures,” British Medical Journal, vol. 312, pp. 1254–1259, 1996. 1689 99,3 I

14 R. M. Neer, C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich, J. Y. Reginster, A. B. Hodsman, E. F. Eriksen, S. Ish-Shalom, H. K. Genant, O. H. Wang, and B. H. Mitlak, “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” Lancet, vol. 344, pp. 1434–1441, 2001. 1686 140,5 I

15 S. R. Cummings, D. M. Black, M. C. Nevitt, W. Browner, J. Cauley, K. Ensrud, H. K. Genant, L. Palermo, J. Scott, and T. M. Vogt, “Bone-density at various sites for prediction of hip-fractures,” The New England Journal of Medicine, vol. 341, pp. 72–75, 1993. 1667 83,3 I

16 W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Cell, vol. 423, pp. 337–342, 2003. 1651 165,1 N/A

17 P. Soriano, C. Montgomery, R. Geske, and A. Bradley, “Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice,” Nature, vol. 64, pp. 693–702, 1991. 1609 73,1 N/A

18 J. A. Kanis, L. J. Melton, C. Christiansen, C. C. Johnston, and N. Khaltaev, “Perspective-the diagnosis of osteoporosis,” Cell, vol. 9, pp. 1137–1141, 1994. 1532 80,6 N/A

19 F. Otto, A. P. Thornell, T. Crompton, A. Denzel, K. C. Gilmour, I. R. Rosewell, G. W. H. Stamp, R. S. P. Beddington, S. Mundlos, B. R. Olsen, P. B. Selby, and M. J. Owen, “Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development,” Journal of Bone and Mineral Research, vol. 89, pp. 765–771, 1997. 1529 95,5 N/A

20 U. A. Liberman, S. R. Weiss, J. Broll, H. W. Minne, H. Quan, N. H. Bell, J. Rodriguezportales, R. W. Downs, J. Dequeker, M. Favus, E. Seeman, R. R. Recker, T. Capizzi, A. C. Santora, A. Lombardi, R. V. Shah, L. J. Hirsch, and D. B. Karpf, “Effect of oral alendronate on bone-mineral density and the incidence of fractures in postmenopausal osteoporosis,” The New England Journal of Medicine, vol. 333, pp. 1437–1443, 1995. 1484 82,4 I

21 N. A. Morrison, J. C. Qi, A. Tokita, P. J. Kelly, L. Crofts, T. V. Nguyen, P. N. Sambrook, and J. A. Eisman, “Prediction of bone-density from vitamin-d receptor alleles,” Nature, vol. 367, pp. 284–287, 1994. 1372 72,2 N/A

22 S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, vol. 289, pp. 1504–1508, 2000. 1370 105,3 N/A

23 N. Bucay, I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. L. Tan, W. L. Xu, D. L. Lacey, W. J. Boyle, and W. S. Simonet, “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes & Development, vol. 12, pp. 1260–1268, 1998. 1292 86,1 N/A

24 S. T. Harris, N. B. Watts, H. K. Genant, C. D. McKeever, T. Hangartner, M. Keller, C. H. Chesnut, J. Brown, E. F. Eriksen, M. S. Hoseyni, D. W. Axelrod, and P. D. Miller, “Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - a randomized controlled trial,” The  Journal  of the American Medical Association, vol. 282, pp. 1344–1352, 1999. 1291 92,2 I

25 S. R. Cummings, J. L. Kelsey, M. C. Nevitt, and K. J. Odowd, “Epidemiology of osteoporosis and osteoporotic fractures,” Epidemiologic Reviews, vol. 7, pp. 178–208, 1985. 1259 44,9 N/A

26 A. Klibanski, L. Adams-Campbell, T. Bassford, S. N. Blair, S. D. Boden, K. Dickersin, D. R. Gifford, L. Glasse, S. R. Goldring, K. Hruska, S. R. Johnson, L. K. McCauley, and W. E. Russell, “Osteoporosis prevention, diagnosis, and therapy,” The  Journal  of the American Medical Association, vol. 285, pp. 785–795, 2001. 1254 104,5 N/A

27 S. R. Cummings, D. M. Black, D. E. Thompson, W. B. Applegate, E. Barrett-Connor, T. A. Musliner, L. Palermo, R. Prineas, S. M. Rubin, J. C. Scott, T. Vogt, R. Wallace, A. J. Yates, and A. Z. LaCroix, “Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial,” The  Journal  of the American Medical Association, vol. 280, pp. 2077–2082, 1998. 1245 83 I

28 D. R. Bertolini, G. E. Nedwin, and T. S. Bringman, “Stimulation of bone-resorption and inhibition of bone-formation invitro by human-tumor necrosis factors,” Nature, vol. 319, pp. 516–518, 1986. 1176 43,5 N/A

29 B. DawsonHughes, S. S. Harris, E. A. Krall, and G. E. Dallal, “Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older,” The New England Journal of Medicine, vol. 337, pp. 670–676, 1997. 1170 73,1 I

30 P. D. Delmas, N. H. Bjarnason, B. H. Mitlak, A. C. Ravoux, A. S. Shah, W. J. Huster, M. Draper, and C. Christiansen, “Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women,” The New England Journal of Medicine, vol. 337, pp. 1641–1647, 1997. 1164 72,7 I

31 T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, T. J. Martin, “Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families,” Endocrine Reviews, vol. 20, pp. 345–357, 1999. 1162 83 N/A

32 K. Nakashima, X. Zhou, G. Kunkel, Z. P. Zhang, J. M. Deng, R. R. Behringer, and B. de Crombrugghe, “The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation,” Cell, vol. 108, pp. 17–29, 2002. 1143 103,9 N/A

33 A. M. Parfitt, C. H. E. Mathews, A. R. Villanueva, M. Kleerekoper, B. Frame, and D.S. Rao, “ Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis-implications for the microanatomic and cellular mechanisms of bone loss,” The Journal of Clinical Investigation, vol. 72, pp. 1396–1409, 1983. 1117 37,2 N/A

34 S. R. Cummings, and L. J. Melton, “Epidemiology and outcomes of osteoporotic fractures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 359, pp. 1761–1767, 2002. 1089 99 N/A

35 E. A. Wang, V. Rosen, J. S. Dalessandro, M. Bauduy, P. Cordes, T. Harada, D. I. Israel, R. M. Hewick, K. M. Kerns, P. Lapan, D. P. Luxenberg, D. McQuaid, I. K. Moutsatsos, J. Nove, and J. M. Wozney, “Recombinant human bone morphogenetic protein induces bone-formation,” Lancet, vol. 87, pp. 2220–2224, 1990. 1077 46,8 N/A

36 S. C. Manolagas, and R. L. Jilka, “Mechanisms of disease - bone-marrow, cytokines, and bone remodeling - emerging insights into the pathophysiology of osteoporosis,” The New England Journal of Medicine,vol. 332, pp. 305–311, 1995. 1047 58,1 N/A

37 C. Cooper, G. Campion, and L. J. Melton, “Hip-fractures in the elderly - a worldwide projection,” Osteoporosis International,vol. 2, pp. 285–289, 1992. 1037 49,3 N/A

38 H. K. Genant, C. Y. Wu, C. Vankuijk, and M. C. Nevitt, “Vertebral fracture assessment using a semiquantitative technique,” Science, vol. 8, pp. 1137–1148, 1993. 1018 50,9 III

39 Y. Q. Gong, R. B. Slee, N. Fukai, Y. Q. Gong, R. B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A. M. Reginato, H. W. Wang, T. Cundy, F. H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W. N. Adkins, J. Allgrove, M. Arslan-Kirchner, J. A. Batch, P. Beighton, G. C. M. Black, R. G. Boles, L. M. Boon, C. Borrone, H. G. Brunner, G. F. Carle, B. Dallapiccola, A. De Paepe, B. Floege, M. L. Halfhide, B. Hall, R. C. Hennekam, T. Hirose, A. Jans, H. Juppner, C. A. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. LaCombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R. S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. Superti-Furga, W. Swoboda, M. J. van den Boogaard, W. Van Hul, M. Vikkula, M. Votruba, B. Zabel, T. Garcia, R. Baron, B. R. Olsen, and M. L. Warman, “LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development,” Cell, vol. 107, pp. 513–523, 2001. 1009 84 N/A

40 R. L. Jilka, G. Hangoc, G. Girasole, G. Passeri, D. C. Williams, J. S. Abrams, B. Boyce, H. Broxmeyer, and S. C. Manolagas, “Increased osteoclast development after estrogen loss - mediation by interleukin-6,” The American Journal of Clinical Nutrition, vol. 257, pp. 88–91, 1992. 1008 48 N/A

41 R. B. Mazess, H. S. Barden, J. P. Bisek, and J. Hanson, “Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition,” Journal of Bone and Mineral Research, vol. 51, pp. 1106–1112, 1990. 1000 43,4 III

42 B. L. Riggs, H. W. Wahner, W. L. Dunn, R. B. Mazess, K. P. Offord, and L. J. Melton, “Differential changes in bone-mineral density of the appendicular and axial skeleton with aging - relationship to spinal osteoporosis,” The Journal of Clinical Investigation, vol. 67, pp. 328–335, 1981. 971 30,3 III

43 C. Maniatopoulos, J. Sodek, and A. H. Melcher, “Bone-formation invitro by stromal cells obtained from bone-marrow of young-adult rats,” Cell and Tissue Research, vol. 254, pp. 317–330, 1988. 964 38,5 N/A

44 M. R. McClung, P. Geusens, P. D. Miller, H. Zippel, W. G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P. J. Meunier, J. Y. Reginster, R. D. Wasnich, M. Greenwald, J. Kaufman, and C. H. Chestnut, “Effect of risedronate on the risk of hip fracture in elderly women,” The New England Journal of Medicine, vol. 344, pp. 333–340, 2001. 954 79,5 I

45 P. Ducy, M. Amling, S. Takeda, M. Priemel, A. F. Schilling, F. T. Beil, J. H. Shen, C. Vinson, J. M. Rueger, and G. Karsenty, “Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass,” Cell, vol. 100, pp. 197–207, 2000. 946 72,7 N/A

46 R. Lindsay, D. M. Hart, J. M. Aitken, E. B. MacDonald, J. B. Anderson, and A. C. Clarke, “Long-term prevention of postmenopausal osteoporosis by estrogen - evidence for an increased bone mass after delayed onset of estrogen-treatment,” Lancet, vol. 1, pp. 1038–1041, 1976. 938 25,3 II

47 H. L. Hsu, D. L. Lacey, C. R. Dunstan, I. Solovyev, A. Colombero, E. Timms, H. L. Tan, G. Elliott, M. J. Kelley, I. Sarosi, L. Wang, X. Z. Xia, R. Elliott, L. Chiu, T. Black, S. Scully, C. Capparelli, S. Morony, G. Shimamoto, M. B. Bass, and W. J. Boyle, “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,” Nature, vol. 96, pp. 3540–3545, 1999. 904 64,5 N/A

48 M. Gowen, D. D. Wood, E. J. Ihrie, M. K. B. McGuire, and R. G. G. Russell, “An interleukin-1 like factor stimulates bone-resorption in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 306, pp. 378–380, 1983. 903 30,1 N/A

49 D. C. Klein, and L. G. Raisz, “Prostaglandins - stimulation of bone resorption in tissue culture,” Endocrinology, vol. 86, pp. 1436–40, 1970. 880 20,4 N/A

50 S. C. Manolagas, “Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” American Journal of Medicine, vol. 21, pp. 115–137, 2000. 877 67,4 N/A